The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2020 | Academic vs. commercial CAR T-cell products
Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, compares academic and commercial CAR T-cell products. Academic products give more flexibility to treat patients and have a lower cost, but from the regulatory perspective, commercial products may be preferable. Prof. Nagler believes there is room for both academic and commercial CAR T-cell products. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
